

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(烟台)股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9995)*

ANNOUNCEMENT ON THE ADJUSTMENT TO THE UPPER LIMIT OF THE PRICE OF A SHARE REPURCHASE

Reference is made to (i) the announcement of RemeGen Co., Ltd. (榮昌生物製藥(烟台)股份有限公司) (the “**Company**”) dated December 25, 2025 (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement, the Upper Price Limit Adjustment Resolution and the Share Repurchase Plan.

I. INFORMATION REGARDING THE SHARE REPURCHASE PLAN

The Company convened the thirty-second meeting of the second session of the Board of Directors on December 15, 2025, considered and approved the Resolution on the *Plan for Repurchase the Company's Shares by Way of Centralized Bidding*. It was agreed that the Company shall use its own funds and/or self-raised funds to repurchase part of the Company's issued RMB-denominated ordinary shares (A shares) by way of centralized bidding. The total amount of funds proposed for the repurchase shall be not less than RMB20 million (inclusive) and not more than RMB40 million (inclusive). The repurchased shares will be used for an employee stock ownership plan or equity incentive at an appropriate time in the future. The repurchase price shall not exceed RMB95 per share (inclusive). The repurchase period shall be within 12 months from the date the Company's Board of Directors considered and approved the repurchase plan.

For details, please refer to the *Plan of RemeGen on Share Repurchase by Way of Centralized Bidding* (Announcement No.: 2025-055) and the *Report on Share Repurchase by Way of Centralized Bidding of RemeGen Co., Ltd.* (Announcement No.: 2025-058) disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on December 16, 2025 and December 23, 2025, respectively.

II. PROGRESS OF THE SHARE REPURCHASE

As of the date of this announcement, the Company has not commenced the share repurchase yet.

The share repurchase complies with the provisions of relevant laws and regulations and the requirements of the Company's repurchase plan.

III. ADJUSTMENT TO THE UPPER LIMIT OF THE PRICE OF THE 2025 FIRST SHARE REPURCHASE

Given the recent continuous situation where the Company's stock price has exceeded the upper limit of the repurchase price of RMB95 per share (inclusive) stipulated in the share repurchase plan, based on confidence in the Company's future sustainable and stable development and recognition of the Company's value, and to ensure the smooth implementation of the share repurchase plan, the Company proposes to adjust the upper limit of the repurchase price from RMB95 per share (inclusive) to RMB116 per share (inclusive).

Save for the aforementioned adjustment to the upper limit of the share repurchase price, all other contents of the share repurchase plan remain unchanged.

IV. IMPACT OF THE ADJUSTMENT ON THE COMPANY

The plan adjustment complies with relevant regulations such as the Company Law, the Rules on Share Repurchases by Listed Companies, the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 – Share Repurchases, and the *Company's Articles of Association*. The Company, having comprehensively considered factors including changes in the securities market and the progress of the share repurchase, proposes to adjust the upper limit of the share repurchase price to RMB116 per share (inclusive). The adjusted upper limit of the share repurchase price does not exceed 150% of the average trading price of the Company's shares over the 30 trading days prior to the Board approving the Resolution on Adjusting the Upper Limit of the Share Repurchase Price.

V. DECISION-MAKING PROCEDURES FOLLOWED FOR THIS ADJUSTMENT TO THE SHARE REPURCHASE PLAN

The Company convened the thirty-fifth meeting of the second session of the Board of Directors on January 14, 2026, considered and approved the Resolution on Adjusting the Upper Limit of the Share Repurchase Price, agreeing to adjust the upper limit of the share repurchase price from RMB95 per share (inclusive) to RMB116 per share (inclusive). Save for the aforementioned adjustment, all other contents of the share repurchase plan remain unchanged. According to the relevant provisions of the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 – Share Repurchases and the *Company's Articles of Association*, the adjustment of the upper limit of the share repurchase price has been approved by a resolution of a Board meeting attended by more than two-thirds of the directors and does not require submission to the Company's shareholders' meeting for consideration.

If the prices of the Company's A Shares continuously exceed the upper limit of the price for the share repurchase with the share repurchase period, there is a risk that the share repurchase plan cannot be successfully implemented. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board

RemeGen Co., Ltd.*

Mr. Wang Weidong

Chairman and executive Director

Yantai, The People's Republic of China

January 15, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* For identification purpose only